Results 151 to 160 of about 644,429 (317)

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

Arthritis &Rheumatology, EarlyView.
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis, Denis Mongin, Denis Choquette, Louis Coupal, Catalin Codreanu, Florenzo Iannone, Roberto Caporali, Tore K. Kvien, Sella Provan, Ruth Fritsch‐Stork, Dan Nordström, Nina Trokovic, Karel Pavelka, Jakub Závada, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Irini Flouri, Céline Lamacchia, Michele Iudici, Delphine Courvoisier, Kim Lauper, Axel Finckh   +22 more
wiley   +1 more source

Recovery and Rehabilitation after Myocardial Infarction [PDF]

, 1978
This study has been undertaken within the rehabilitation research programme of the Health Servicbs Research Unit. It has been directed by Professor Warren and under the day-to-day management of Mr. Lee. Mr.
Lee, R.H.
core  

Inferring Rheumatoid Arthritis Disease Activity Status From the Electronic Health Records Across Health Systems

Arthritis &Rheumatology, EarlyView.
Objective Disease activity plays a central role in rheumatoid arthritis (RA) clinical studies. The inconsistent availability of data on disease activity in real‐world electronic health records (EHRs) data has limited the ability to generate real‐world evidence (RWE).
David Cheng, Xuan Wang, Gregory C. McDermott, Jennifer S. Hanberg, Zoe Love, Katherine Zhong, Mary Jeffway, Jue Hou, Vidul Panickan, Rahul Sangar, Ying Qi, Connor Melley, Lauren Costa, Dakota Feil, Rachael Matty, Dana Weisenfeld, Abisayo Animashaun, Aimee Schreiner, Sara Morini, Lauren Rusnak, Andrew Cagan, Misti Paudel, J. Michael Gaziano, Brian Sauer, Michael Weinblatt, Joshua Baker, Bryant England, Yuk‐Lam Ho, Kelly Cho, Paul Monach, Grant W. Cannon, Nancy Shadick, Ted R. Mikuls, Tianxi Cai, Katherine P. Liao   +34 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Nonadherence and uncontrolled arterial hypertension in Croatia—Insights from the May Measurement Month 2023 campaign and Hunting the silent killer programme

British Journal of Clinical Pharmacology, EarlyView.
Aims To determine the prevalence of non‐adherence to antihypertensive medicines and to identify demographic and behavioral factors associated with non‐adherence in subjects enrolled in the May Measurement Month (MMM) 2023, as part of the permanent public health action Hunting the silent killer.
Valerija Bralić Lang, Ana Soldo, Olgica Velkovski Škopić, Sunčana Vlah Tomičević, Tin Šaban, Andrej Belančić, Ana Jelaković, Josipa Josipović, Mihaela Marinović Glavić, Ivan Pećin, Luka Prgomet, Tajana Željković Vrkić, Bojan Jelaković   +12 more
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

The Most Frequent and Fatal Types of Acute Myocardial Infarction in Isfahan, Iran

مجله دانشکده پزشکی اصفهان, 2013
Cardiovascular diseases, particularly coronary artery diseases, are the first cause of death in Iran. Patients with acute myocardial infarction who were hospitalized in hospitals of Isfahan (Iran) during 2000-09 were identified and followed up for 28 ...
Abdollah Mohammadian Hafshejani, Shahram Oveisgharan, Nizal Sarrafzadegan   +2 more
doaj  

Myocardial Infarction and Marijuana

Clinical Toxicology, 1981
Coutselinis, A., Michalodimitrakis, M.
openaire   +3 more sources

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source